NovoCure Limited (NVCR) Financial Analysis & Valuation | Quarter Chart
NovoCure Limited (NVCR)
NVCRPrice: $10.58
Fair Value: 🔒
🔒score
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Opt... more
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercializatio... more
Description
Shares
| Market Cap | $1.20B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Instruments & Supplies |
| Country | JE | CEO | Frank Leonard |
| IPO Date | 2015-10-01 | CAGR | 0.41% |
| Employees | 1,488 | Website | www.novocure.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
NVCR chart loading...
Fundamentals
Technicals
| Enterprise Value | $1.15B | P/E Ratio | -8.67 |
| Forward P/E | -9.08 | PEG Ratio | — |
| P/S Ratio | 0.01 | P/B Ratio | 0.01 |
| P/CF Ratio | -0.14 | P/FCF Ratio | -0.07 |
| EPS | $-1.22 | EPS Growth 1Y | -21.79% |
| EPS Growth 3Y | 37.92% | EPS Growth 5Y | -742.11% |
| Revenue Growth 1Y | 8.28% | Gross Margin | 0.75% |
| Operating Margin | -0.23% | Profit Margin | -0.21% |
| ROE | -0.39% | ROA | — |
| ROCE | 0.69% | Current Ratio | — |
| Quick Ratio | — | Cash Ratio | — |
| Debt/Equity | 0.3 | Interest Coverage | — |
| Altman Z Score | — | Piotroski Score | 2 |